China Resources Pharmaceutical Holdings Co., Ltd.

(Hong Kong, 10 April 2026) - AilsynBio, an AI-driven drug discovery company, held a Project Cooperation Agreement Signing Ceremony today at the Hong Kong Science Park, announcing a comprehensive project cooperation agreement with Dong-E-E-Jiao Co., Ltd. (000423.SZ). This partnership marks a profound cross-sector integration of Artificial Intelligence (AI) and traditional medicine, aiming to empower biopharmaceutical innovation through technological means. The ceremony brought together influential leaders and experts from industry, academia, and research sectors, including senior representatives from China Resources Pharmaceutical Group, Hong Kong Science and Technology Parks Corporation (HKSTP), and The University of Hong Kong (HKU), to witness this significant milestone. Derek Chim, Head of Startup Ecosystem and Development of HKSTP, said: “This cooperation reflects exactly what Incu-Bio was built to achieve — nurturing startups that partner with global leaders like Dong-E-E-Jiao. It’s proof that the ecosystem works and that our approach delivers real results. It also demonstrates HKSTP’s growing focus on biotech innovation and AI, which now spans the entire healthcare value chain. We congratulate both teams on this achievement and look forward to seeing more collaborations like this emerge from Hong Kong’s vibrant innovation community.” Dr Bo Chen, Chief Scientist of China Resources Pharmaceutical, noted: “This collaboration with Dong-E-E-Jiao and AilsynBio is an important practice for China Resources Pharmaceutical in promoting the modernization of Traditional Chinese Medicine (TCM). It represents a deep integration of industry, academia, and research in the field of 'AI + TCM' between Mainland China and Hong Kong. We look forward to integrating scientific research and industrial resources from both regions to solve the challenges of TCM's mechanisms of action and provide an innovative path for TCM to evolve from empirical medicine to evidence-based medicine.” Liang Zheng, Vice President of Dong-E-E-Jiao, stated: “As a core strategic product for Dong-E-E-Jiao, deepening the scientific value of Compound E-Jiao Syrup is crucial for our brand upgrade. This cooperation will strengthen the scientific foundation of our products in the field of women’s health, helping Dong-E-E-Jiao accelerate into a new stage of ‘reshaping TCM wisdom through technological innovation.’” Pierre Wang, Managing Director of HKU Versitech Limited, stated: “HKU Versitech is honored to witness this project cooperation between HKU spin-off AilsynBio Ltd. and China Resources Pharmaceutical Group Limited subsidiary Dong-E E-Jiao, a partnership that exemplifies the successful translation of world-class academic research into high-impact industrial applications. This cooperation will continue to serve as a vital catalyst for the company’s rapid international growth and its mission to scale cutting-edge biotechnology globally.” Looking ahead, the two parties will focus on three key collaborative directions: Advancing AI-driven innovation: Leveraging AilsynBio’s AI drug discovery platform to accelerate biopharmaceutical R&D processes. Launching specialized research: Engaging in in-depth cooperation on the "Premature Ovarian Insufficiency (POI)" research project. Promoting cross-border fusion: Exploring the integration of biotechnology, AI, and traditional medicine to jointly create a new paradigm for the health industry. During the ceremony, AilsynBio and Dong-E-E-Jiao signed the agreement on behalf of their respective organizations. The signing was witnessed by Dr Bo Chen, Chief Scientist of China Resources Pharmaceutical; Eric Or, Chief Ecosystem Development Officer of HKSTP; and Pierre Wang, Managing Director of HKU Versitech. AilsynBio stated that this cooperation is not only a combination of technologies but also a strategic layout for future healthcare innovation. By leveraging AI technology, the partnership aims to inject technological vitality into traditional medicine for the benefit of more patients.

TAIPEI, Taiwan, March 30, 2026 (GLOBE NEWSWIRE) -- AP Biosciences, a clinical-stage biopharmaceutical company dedicated to transforming cancer therapy through development of innovative bispecific antibodies, today announced the finalization of an amendment to its development collaboration with Tasly Pharmaceutical Group Co.LTD., establishing a supplementary framework for the anticipated out-licensing of AP505 (B1962) outside the original agreement’s designated Territory (which includes PRC, Hong Kong and Macau under the original License Development and Commercialization Agreement). AP505 (B1962) has completed a Phase 1 clinical study and is currently being evaluated in Phase 2 trials led by Tasly in-Territory for advanced solid tumors, further supporting its translational potential and advancement toward later-stage development. The amended deal around AP505 (B1962) pairs Tasly’s proven clinical development efficiency in-Territory with AP Biosciences’ global development and partnering strategy, a collaboration structure designed to accelerate AP505 (B1962)’s continued advancement while maximizing its value both in- and ex-Territory, in international markets. “This amendment reflects the shared commitment between AP Biosciences and Tasly to accelerate the development and commercialization of AP505 (B1962) for patients globally,” said Jeng Her, Ph.D., Founder and Chief Executive Officer of AP Biosciences. “By establishing clear and rapid pathways for technology transfer, clinical data sharing, and clinical supply, this agreement enhances our readiness to engage potential partners and progress AP505 (B1962) toward ex-Territory clinical development.” Under the amended terms, Tasly will support AP Biosciences’ global development and partnering efforts by providing relevant clinical data, regulatory materials, and clinical supply for ex-Territory studies, on a revenue-sharing basis. The agreement also establishes a framework for technology transfer and collaboration with potential third-party partners in ex-Territory. Locust Walk Partners, LLC, served as the lead financial advisor of the collaboration agreement amendment. For more information about AP Biosciences and its bispecific antibody pipeline, please visit: About AP505 (B1962) AP505 (B1962) is a bispecific antibody engineered to target two critical and complementary pathways in cancer biology. By simultaneously binding programmed cell death ligand-1 (PD-L1) and vascular endothelial growth factor (VEGF) , AP505 (B1962) aims to both release immune suppression on T cells and inhibit tumor-driven angiogenesis, thereby enhancing anti-tumor activity compared to conventional monotherapies. Its symmetric IgG-based fusion protein structure increases manufacturability and stability, and enables purification using standard monoclonal antibody processes, while its dual-pathway mechanism is poised to address major unmet needs in indications such as hepatocellular carcinoma and pMMR colorectal cancer, where single-agent immunotherapies have shown limited efficacy. About AP Biosciences AP Biosciences (6945:Taipei) is a Taiwan-based clinical-stage biopharmaceutical company committed to developing innovative antibody-based therapies for cancer and other diseases. Applying its proprietary Omni-Mab and T-cube platforms, AP Biosciences is pioneering next generation bispecific antibodies that activate the immune system precisely where it’s needed, for both established and treatment-resistant cancers. AP Biosciences Contact Spike Lo AP Biosciences pr@apbioinc.com Media Contact Mike Tattory LifeSci Communications mtattory@lifescicomms.com

WASHINGTON, Dec. 26, 2025 /PRNewswire/ -- Over the past decade, China has evolved from a biotechnology follower into an increasingly influential global innovator. Once reliant on Western pharmaceutical companies for advanced therapies, the country is now building a homegrown biotech ecosystem that addresses domestic healthcare needs while contributing to global drug development. Continue Reading Eugene Jiaxian Wang, HELP Therapeutics Founder & CEO This shift is driven by sustained policy support, rising R&D investment, and a strong life sciences talent base. China's R&D spending has grown from below 1% of GDP two decades ago to nearly 2.7% in 2023, approaching U.S. levels. With the world's largest cohort of STEM graduates and a rapidly expanding clinical trial infrastructure, China has surpassed the United States in total clinical trials, reinforcing its role in global biomedical research. China's growing international presence is increasingly visible on leading scientific stages. HELP Therapeutics on the Global Stage At the 22nd Global Cardiovascular Clinical Trialists Forum (CVCT), a leading platform for cardiovascular research, Dr. Eugene Jiaxian Wang, Founder and CEO of HELP Therapeutics, presented China's latest clinical progress in cell therapy for heart failure. During the session "Cell Therapy Heart Failure Trials: Cells, Delivery, and Disease-Specific Strategies," Dr. Wang shared translational and clinical data from iPSC-derived cardiomyocyte programs, highlighting China's advancement of cell therapies into rigorously designed, multinational clinical development. HELP's lead program, HiCM-188, is the world's first iPSC-derived regenerative therapy for advanced heart failure to receive IND clearance in both China and the United States. The therapy is currently in Phase II trials in China and Phase I/II trials across the U.S., Singapore, and Thailand, supported by more than six years of follow-up demonstrating robust safety and encouraging efficacy. HELP has also entered a strategic co-development and commercialization partnership with China Resources Sanjiu Pharmaceutical to accelerate clinical translation. From Participants to Leaders China's biotech momentum reflects structural advantages including large patient populations, integrated clinical infrastructure, sustained capital support, and cost-efficient R&D capabilities. These strengths have driven growth in cross-border licensing, with Chinese-origin molecules now accounting for nearly 30% of global drug development. As global healthcare systems confront aging populations and chronic disease, China's biotechnology sector is becoming an indispensable contributor to global innovation. About HELP Therapeutics Help Therapeutics is a pioneering biotechnology company dedicated to revolutionizing the treatment of degenerative diseases through stem cell and regenerative medicine technologies. Media Contact: Mengying Tan +86 13261002597 [email protected] SOURCE HELP Therapeutics 21% more press release views with Request a Demo